Rates of sensitivity reactions to aspirin: Problems in interpreting the data

Chian K Kwoh, Alvan R. Feinstein

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This work was done to determine the reasons for variation in the reported rates-ranging from <1% to >50%-of sensitivity to aspirin and cross-reactivity to acetaminophen and ibuprofen. In 47 studies that reported rates of sensitivity and in 23 reports that contained series of sensitive patients, we examined the research setting, source of patients, clinical attributes of the study group, admission process, and selection, operational definition, and method of determining sensitivity reactions. In five studies with reasonably well-specified methods, the reported sensitivity rates to aspirin were lowest (0.3% to 0.9%) for patients without allergic tendencies, higher in asthmatics, and highest if patients had nasal polyps or severe atopy. Although not determined in any of these studies, the rate of sensitivity in a general (nonclinical) population would doubtlessly be substantially lower than the rate of three per 1000 reported for nonallergic patients. The admixture of different clinical groups, varying definitions, and ascertainment of a sensitivity reaction seem to be responsible for the variations in the reported rates of sensitivity and cross-reactivity.

Original languageEnglish (US)
Pages (from-to)494-505
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume40
Issue number5
StatePublished - Nov 1986
Externally publishedYes

Fingerprint

Aspirin
Nasal Polyps
Group Processes
Ibuprofen
Acetaminophen
Research
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Rates of sensitivity reactions to aspirin : Problems in interpreting the data. / Kwoh, Chian K; Feinstein, Alvan R.

In: Clinical Pharmacology and Therapeutics, Vol. 40, No. 5, 11.1986, p. 494-505.

Research output: Contribution to journalArticle

@article{f6066105f90d42f79fd07e705e4fe384,
title = "Rates of sensitivity reactions to aspirin: Problems in interpreting the data",
abstract = "This work was done to determine the reasons for variation in the reported rates-ranging from <1{\%} to >50{\%}-of sensitivity to aspirin and cross-reactivity to acetaminophen and ibuprofen. In 47 studies that reported rates of sensitivity and in 23 reports that contained series of sensitive patients, we examined the research setting, source of patients, clinical attributes of the study group, admission process, and selection, operational definition, and method of determining sensitivity reactions. In five studies with reasonably well-specified methods, the reported sensitivity rates to aspirin were lowest (0.3{\%} to 0.9{\%}) for patients without allergic tendencies, higher in asthmatics, and highest if patients had nasal polyps or severe atopy. Although not determined in any of these studies, the rate of sensitivity in a general (nonclinical) population would doubtlessly be substantially lower than the rate of three per 1000 reported for nonallergic patients. The admixture of different clinical groups, varying definitions, and ascertainment of a sensitivity reaction seem to be responsible for the variations in the reported rates of sensitivity and cross-reactivity.",
author = "Kwoh, {Chian K} and Feinstein, {Alvan R.}",
year = "1986",
month = "11",
language = "English (US)",
volume = "40",
pages = "494--505",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Rates of sensitivity reactions to aspirin

T2 - Problems in interpreting the data

AU - Kwoh, Chian K

AU - Feinstein, Alvan R.

PY - 1986/11

Y1 - 1986/11

N2 - This work was done to determine the reasons for variation in the reported rates-ranging from <1% to >50%-of sensitivity to aspirin and cross-reactivity to acetaminophen and ibuprofen. In 47 studies that reported rates of sensitivity and in 23 reports that contained series of sensitive patients, we examined the research setting, source of patients, clinical attributes of the study group, admission process, and selection, operational definition, and method of determining sensitivity reactions. In five studies with reasonably well-specified methods, the reported sensitivity rates to aspirin were lowest (0.3% to 0.9%) for patients without allergic tendencies, higher in asthmatics, and highest if patients had nasal polyps or severe atopy. Although not determined in any of these studies, the rate of sensitivity in a general (nonclinical) population would doubtlessly be substantially lower than the rate of three per 1000 reported for nonallergic patients. The admixture of different clinical groups, varying definitions, and ascertainment of a sensitivity reaction seem to be responsible for the variations in the reported rates of sensitivity and cross-reactivity.

AB - This work was done to determine the reasons for variation in the reported rates-ranging from <1% to >50%-of sensitivity to aspirin and cross-reactivity to acetaminophen and ibuprofen. In 47 studies that reported rates of sensitivity and in 23 reports that contained series of sensitive patients, we examined the research setting, source of patients, clinical attributes of the study group, admission process, and selection, operational definition, and method of determining sensitivity reactions. In five studies with reasonably well-specified methods, the reported sensitivity rates to aspirin were lowest (0.3% to 0.9%) for patients without allergic tendencies, higher in asthmatics, and highest if patients had nasal polyps or severe atopy. Although not determined in any of these studies, the rate of sensitivity in a general (nonclinical) population would doubtlessly be substantially lower than the rate of three per 1000 reported for nonallergic patients. The admixture of different clinical groups, varying definitions, and ascertainment of a sensitivity reaction seem to be responsible for the variations in the reported rates of sensitivity and cross-reactivity.

UR - http://www.scopus.com/inward/record.url?scp=0023010449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023010449&partnerID=8YFLogxK

M3 - Article

C2 - 3769380

AN - SCOPUS:0023010449

VL - 40

SP - 494

EP - 505

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -